- Home
- TYGO vs OVID Comparison
TYGO vs OVID Comparison
Compare TYGO & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TYGO
- OVID
- Stock Information
- Founded
- TYGO 2007
- OVID 2014
- Country
- TYGO United States
- OVID United States
- Employees
- TYGO N/A
- OVID N/A
- Industry
- TYGO Semiconductors
- OVID Biotechnology: Pharmaceutical Preparations
- Sector
- TYGO Technology
- OVID Health Care
- Exchange
- TYGO Nasdaq
- OVID Nasdaq
- Market Cap
- TYGO 116.0M
- OVID 117.3M
- IPO Year
- TYGO N/A
- OVID 2017
- Fundamental
- Price
- TYGO $1.77
- OVID $1.62
- Analyst Decision
- TYGO Strong Buy
- OVID Strong Buy
- Analyst Count
- TYGO 1
- OVID 5
- Target Price
- TYGO $6.00
- OVID $3.60
- AVG Volume (30 Days)
- TYGO 630.6K
- OVID 1.5M
- Earning Date
- TYGO 10-28-2025
- OVID 11-12-2025
- Dividend Yield
- TYGO N/A
- OVID N/A
- EPS Growth
- TYGO N/A
- OVID N/A
- EPS
- TYGO N/A
- OVID N/A
- Revenue
- TYGO $90,781,000.00
- OVID $6,610,000.00
- Revenue This Year
- TYGO $95.15
- OVID $1,081.80
- Revenue Next Year
- TYGO $21.54
- OVID N/A
- P/E Ratio
- TYGO N/A
- OVID N/A
- Revenue Growth
- TYGO 97.41
- OVID 945.89
- 52 Week Low
- TYGO $0.58
- OVID $0.24
- 52 Week High
- TYGO $4.50
- OVID $2.01
- Technical
- Relative Strength Index (RSI)
- TYGO 39.87
- OVID 63.29
- Support Level
- TYGO $1.59
- OVID $1.21
- Resistance Level
- TYGO $4.50
- OVID $1.56
- Average True Range (ATR)
- TYGO 0.37
- OVID 0.12
- MACD
- TYGO -0.03
- OVID 0.04
- Stochastic Oscillator
- TYGO 6.70
- OVID 95.69
About TYGO Tigo Energy Inc.
Tigo Energy Inc designs solar power conversion and storage products that provide customers with more choice and flexibility. Its mission is to deliver smart hardware and software solutions that enhance safety, increase energy yield, and lower operating costs of residential, commercial, and utility-scale solar systems. Geographically the company generates revenue from EMEA, Americas, and APAC.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.